The aesthetic injectable market in the United States is expected to reach a projected revenue of US$ 8,074.5 million by 2033. A compound annual growth rate of 9.2% is expected of the United States aesthetic injectable market from 2026 to 2033.
Ipsen SA, AbbVie Inc, Merz Pharma, Galderma Group AG Registered Shares, Prollenium Medical Technologies, Suneva Medical, Sinclair Pharma plc, Medytox, Revance Therapeutics Inc
Other key industry trends
In terms of revenue, U.S. accounted for 35.7% of the global aesthetic injectable market in 2025.
Country-wise, U.S. is expected to lead the global market in terms of revenue in 2033.
In North America, U.S. aesthetic injectable market is projected to lead the regional market in terms of revenue in 2033.
U.S. is the fastest growing regional market in North America and is projected to reach USD 8,074.5 million by 2033.
The U.S. held an 87.2% share of North America aesthetic injectable market. According to a report by the International Society of Aesthetic Plastic Surgery (ISAPS), in 2022, nearly 4,556,970 nonsurgical injectable procedures were performed in the U.S., of which 3,945,282 procedures involved Botox fillers and 521,169 involved HA fillers.
An increase in the number of cosmetic procedures is expected to boost the U.S. aesthetic injectable market over the forecast period. The growing geriatric population in the U.S., susceptible to skin imperfections or diseases, is expected to increase the demand for cosmetic procedures, significantly contributing to market growth over the forecast period.
According to a Population Reference Bureau article, the geriatric population in the region is anticipated to increase by 69% from 2020 to 2060. Furthermore, the country has the highest number of plastic surgeons, which is expected to boost the market growth.
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to Aesthetic Injectable Market will help companies and investors design strategic landscapes.
Botulinum Toxin (Botox) was the largest segment with a revenue share of 50.37% in 2025.
Horizon Databook has segmented the U.S. aesthetic injectable market based on collagen and pmma microspheres, hyaluronic acid, calcium hydroxylapatite (caha), plla, botulinum toxin (botox) covering the revenue growth of each sub-segment from 2021 to 2033.
The U.S. held an 87.2% share of North America aesthetic injectable market. According to a report by the International Society of Aesthetic Plastic Surgery (ISAPS), in 2022, nearly 4,556,970 nonsurgical injectable procedures were performed in the U.S., of which 3,945,282 procedures involved Botox fillers and 521,169 involved HA fillers.
An increase in the number of cosmetic procedures is expected to boost the U.S. aesthetic injectable market over the forecast period. The growing geriatric population in the U.S., susceptible to skin imperfections or diseases, is expected to increase the demand for cosmetic procedures, significantly contributing to market growth over the forecast period.
According to a Population Reference Bureau article, the geriatric population in the region is anticipated to increase by 69% from 2020 to 2060. Furthermore, the country has the highest number of plastic surgeons, which is expected to boost the market growth.
U.S. Aesthetic Injectable Market Product Outlook (Revenue, USD Million , 2021-2033)
Collagen and PMMA Microspheres
Hyaluronic Acid
Calcium Hydroxylapatite (CaHA)
PLLA
PCL
PN/PDRN
Botulinum Toxin (Botox)
U.S. Aesthetic Injectable Market Application Outlook (Revenue, USD Million , 2021-2033)
Wrinkle Correction
Lip Augmentation
Facial Contouring
Scar Treatment
Volume Loss Restoration
Others
U.S. Aesthetic Injectable Market End Use Outlook (Revenue, USD Million , 2021-2033)
MedSpas
Aesthetic Surgery Centers
Hospitals
Others
Reasons to subscribe to Aesthetic Injectable Market databook
Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.
Target buyers of Aesthetic Injectable Market databook
Our clientele includes a mix of Aesthetic Injectable Market companies, investment firms, advisory firms & academic institutions.
30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.
Horizon Databook provides a detailed overview of country-level data and insights on the U.S. Aesthetic Injectable Market, including forecasts for subscribers. This country databook contains high-level insights into U.S. Aesthetic Injectable Market from 2021 to 2033, including revenue numbers, major trends, and company profiles.
U.S. Aesthetic Injectable Market, 2021-2033 (US$M)